VYNE Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Jun '25 Jun 20, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Market Capitalization	15	49	33	9	55	265	Upgrade
Market Cap Growth	-45.87%	51.96%	273.57%	-84.05%	-79.42%	-	Upgrade
Enterprise Value	-35	-21	17	-27	3	224	Upgrade
Last Close Price	0.89	3.35	2.33	2.70	18.36	113.76	Upgrade
PS Ratio	62.69	98.64	76.70	18.25	58.63	12.64	Upgrade
PB Ratio	0.32	0.95	0.37	0.28	1.12	7.08	Upgrade
P/TBV Ratio	0.34	0.95	0.37	0.28	1.12	7.08	Upgrade
EV/Sales Ratio	-	-	40.27	-	3.58	10.69	Upgrade
Debt / Equity Ratio	0.00	0.00	0.00	-	0.01	0.93	Upgrade
Asset Turnover	0.01	0.01	0.01	0.01	0.01	0.24	Upgrade
Inventory Turnover	-	-	-	-	-	0.32	Upgrade
Quick Ratio	4.09	4.15	12.37	3.84	2.71	3.42	Upgrade
Current Ratio	4.47	4.35	12.73	4.10	3.43	4.01	Upgrade
Return on Equity (ROE)	-66.15%	-56.54%	-46.40%	-84.81%	-102.66%	-928.19%	Upgrade
Return on Assets (ROA)	-38.36%	-33.14%	-26.42%	-39.77%	-30.25%	-81.10%	Upgrade
Return on Capital (ROIC)	-44.48%	-38.65%	-30.39%	-53.32%	-40.11%	-114.09%	Upgrade
Earnings Yield	-284.50%	-80.61%	-87.49%	-266.62%	-134.33%	-96.35%	Upgrade
FCF Yield	-253.30%	-68.98%	-77.92%	-335.43%	-103.26%	-51.72%	Upgrade
Buyback Yield / Dilution	-111.95%	-314.57%	-222.44%	-11.44%	-58.75%	-282.06%	Upgrade

Updated May 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q